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Abstract 
Background: Malaria is one of the major causes of childhood death in sub‑Saharan countries. A reliable estimation 
of malaria prevalence is important to guide and monitor progress toward control and elimination. The aim of the 
study was to estimate the true prevalence of malaria in children under five in the Democratic Republic of the Congo, 
Uganda and Kenya, using a Bayesian modelling framework that combined in a novel way malaria data from national 
household surveys with external information about the sensitivity and specificity of the malaria diagnostic methods 
used in those surveys—i.e., rapid diagnostic tests and light microscopy.
Methods: Data were used from the Demographic and Health Surveys (DHS) and Malaria Indicator Surveys (MIS) 
conducted in the Democratic Republic of the Congo (DHS 2013–2014), Uganda (MIS 2014–2015) and Kenya (MIS 2015), 
where information on infection status using rapid diagnostic tests and/or light microscopy was available for 13,573 chil‑
dren. True prevalence was estimated using a Bayesian model that accounted for the conditional dependence between 
the two diagnostic methods, and the uncertainty of their sensitivities and specificities obtained from expert opinion.
Results: The estimated true malaria prevalence was 20% (95% uncertainty interval [UI] 17%–23%) in the Democratic 
Republic of the Congo, 22% (95% UI 9–32%) in Uganda and 1% (95% UI 0–3%) in Kenya. According to the model esti‑
mations, rapid diagnostic tests had a satisfactory sensitivity and specificity, and light microscopy had a variable sensitiv‑
ity, but a satisfactory specificity. Adding reported history of fever in the previous 14 days as a third diagnostic method to 
the model did not affect model estimates, highlighting the poor performance of this indicator as a malaria diagnostic.
Conclusions: In the absence of a gold standard test, Bayesian models can assist in the optimal estimation of the 
malaria burden, using individual results from several tests and expert opinion about the performance of those tests.
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Background
Despite a worldwide decline in the malaria burden over 
the past 15 years, millions of people mainly across Africa 
still lack access to the tools they need to prevent and treat 
the disease. In 2015, about 200 million cases and 400,000 
deaths due to malaria were estimated in the African con-
tinent, representing 90% of the world’s malaria burden 
[1].
In countries with poor systems for tracking malaria 
cases and deaths, as in sub-Saharan Africa countries, 
the prevalence of infections with malarial parasites is 
the most useful indicator of the level of transmission 
and, therefore, the most reliable means to understand 
Open Access
Malaria Journal
*Correspondence:  brechtdv@gmail.com 
2 Department of Public Health and Surveillance, Scientific Institute 
of Public Health (WIV‑ISP), Brussels, Belgium
Full list of author information is available at the end of the article
Page 2 of 7Mfueni et al. Malar J  (2018) 17:65 
the impact of control [2, 3]. Two diagnostic methods are 
commonly used in representative African household sur-
veys to confirm whether an individual is infected or not 
with the malaria parasite, allowing for the estimation of 
the malaria prevalence [4, 5]. Light microscopy remains 
the reference method for laboratory confirmation of 
malaria, but it requires skilled microscopists and may be 
hampered by a poor quality of slide preparation or bad 
storage conditions [6, 7]. Rapid diagnostic tests offer a 
simple, fairly inexpensive, and reliable means of diagno-
sis that can be performed by health workers with limited 
training [8]; however, there are many available tests in the 
market with varying accuracy for the detection of malaria 
antigens or live parasite infections [9, 10]. In addition, 
household surveys collect information of history of fever 
in the previous 14 days, allowing for the estimation of the 
prevalence of febrile illness [4, 11].
In general, the sensitivity and specificity of a malaria 
diagnostic method may vary according to the character-
istics of the surveyed population and other factors, such 
as age, sampling season, presence of cross-reacting dis-
eases, malaria species, parasite density, and the quality of 
laboratory and experience of readers [9, 12]. As a result, 
the apparent prevalence estimated through these diag-
nostic tests may vary widely from one test to another and 
from one context to another. Indeed, the prevalence of 
malaria shown in various surveys differs according to the 
diagnostic method used [13–15].
The aim of this study was to estimate the true preva-
lence of malaria in children under five in the Democratic 
Republic of the Congo, Uganda and Kenya, as well as 
the sensitivity and specificity of the applied diagnostic 
methods. The true prevalence, based on the actual num-
ber of individuals infected by malaria parasite, instead of 
the apparent prevalence, based on the number of posi-
tive diagnostic methods, can be estimated in a Bayesian 
framework. This approach allows combining the opinion 
of experts on the diagnostic method characteristics with 
the obtained diagnostic method results into an optimal 
estimate of the “true” or “informed” prevalence [16–20].
Methods
Population and data collection
The Demographic and Health Surveys (DHS) and 
Malaria Indicator Surveys (MIS) are cross-sectional, 
nationally representative studies conducted in low and 
middle-income countries. For the current study, a DHS 
survey conducted in the Democratic Republic of the 
Congo from August 2013 to February 2014 was used [13], 
as well as two MIS surveys, one conducted in Uganda 
from December 2014 to January 2015 [14], and one in 
Kenya from July to August 2015 [15]. Malaria in children 
under five was diagnosed based on reported history of 
fever in the previous 14 days, rapid diagnostic tests and 
light microscopy.
The surveys used stratified multi-stage sampling. First, 
the countries were divided into small geographic areas 
(clusters) and in each cluster, three strata were created: 
towns, cities and rural or urban areas. In a second stage, 
households were randomly selected within each stratum. 
The interviews were conducted by health workers and/or 
technicians who received prior training on interviewing 
techniques, anthropometric measurement techniques, 
blood sampling, the performance of rapid diagnostic 
tests for the detection of malaria parasite antigens, and 
the preparation of thick films for the detection of para-
sites in blood.
During the survey, all children under 5 years old were 
identified, and their mother and/or guardian was asked 
whether or not the children had been ill with fever any 
time in the past 2 weeks. Then, a finger-prick blood sam-
ple was taken from each child for malaria diagnosis using 
light microscopy and rapid diagnostic tests (SD Bioline 
malaria Ag-Pf in the Democratic Republic of the Congo, 
Paracheck-Pf in Uganda, SD Bioline malaria Ag-Pf/Pan 
in Kenya). Thick and thin blood smears were prepared, 
dried, fixed with methanol, and stained with 2% Giemsa 
(a mixture of methylene blue, eosin, azure B and a sol-
vent). Smears were periodically sent to a national ref-
erence laboratory for microscopic examination. Light 
microscopy was considered negative when the examina-
tion of 100 high power fields did not reveal asexual para-
sites or gametocytes [13–15].
True prevalence estimation
The apparent malaria prevalence with corresponding 95% 
exact confidence intervals (CI) were primarily calculated 
for each country based on two test results: the outcomes 
of rapid diagnostic tests and light microscopy (i.e., posi-
tive or negative for malaria). Since the two test results 
cannot be considered completely independent of each 
other, a Bayesian framework to estimate the true malaria 
prevalence was developed to account for the conditional 
dependence between tests, and to incorporate external 
information on the sensitivity and specificity of those 
tests [20]. This modelling framework took advantage of 
previous work published by Branscum et  al. [21] who 
modelled conditional dependence between two diagnos-
tic methods. Both the design and sample weights of sur-
veys were considered in the calculation of apparent and 
true prevalence [22].
The approach proposed by Branscum et  al. [21] for 
two diagnostic methods models the apparent prevalence 
(AP ) in terms of the true prevalence TP, the condition-
ally independent test sensitivities (SE1, SE2) and the test 
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specificities (SP1, SP2), and the covariances between the 
two tests for infected and non-infected individuals (a, b):
where AP11 is the apparent prevalence of positive results 
in both tests, AP10 is the apparent prevalence of a posi-
tive result in the first test and a negative in the second, 
and so on.
This model was applied in the current study to include 
the results of two conditionally dependent tests—
i.e., rapid diagnostic test (T1) and light microscopy 
(T2). The apparent test results are given by a vector 
x = (x11, x10, x01, x00), with x11 the number of individuals 
testing positive in both tests, x10 the number of individu-
als testing positive in the first but negative in the second, 
and so on. The vector x was assumed to be distributed 
according to a multinomial distribution:
With n =
∑
x the total sample size and 
AP = (AP11,AP10,AP01,AP00) the apparent prevalence 
vector corresponding to each possible combination of 
test results.
Expert opinion allowed deriving prior distributions for 
the test sensitivities and specificities. A Beta (1, 1) prior 
was applied for TP, and Uniform (−0.25, 0.25) priors for 
the covariance between two tests. The boundaries of the 
latter distribution correspond to the natural limits of 
the covariance parameter. To assess the impact of the 
informative priors for the sensitivities and specificities 
of the diagnostic methods, one-way sensitivity analyses 
were performed in which each informative prior was 
one-at-a time replaced by an uninformative Beta (1, 1) 
prior.
Models were implemented independently for the 
three countries. For each model, two chains of 110,000 
iterations were simulated, of which the first 10,000 were 
discarded as burn-in. No thinning was applied. The con-
vergence of the models was assessed by calculating the 
multivariate potential scale reduction factor [23] and 
by assessing trace and density plots. Posterior distribu-
tions were summarized using the mean and a 95% uncer-
tainty interval (UI) defined as the distribution’s 2.5th and 
97.5th  percentile. All models were implemented using 
the prevalence package for R 3.4.3 [24], which builds on 
JAGS to perform Markov Chain Monte Carlo simulations 
using the Gibbs sampler [25].
AP11 = TP[SE1SE2 + a]+ (1− TP)[(1− SP1)(1− SP2)+ b]
AP10 = TP[SE1(1− SE2)− a]+ (1− TP)[(1− SP1)SP2 − b]
AP01 = TP[(1− SE1)SE2 − a]+ (1− TP)[SP1(1− SP2)− b]
AP00 = TP[(1− SE1)(1− SE2)+ a]+ (1− TP)[SP1SP2 + b]
x ∼ multinomial(n,AP)
In a scenario analysis, the 2-test covariance model 
was extended to include the results of reported his-
tory of fever in the previous 14 days as a third diagnos-
tic method. A full description of this 3-test covariance 
model is included in Additional file 1.
Prior information from experts
Prior information on the sensitivity and specificity of 
the diagnostic methods was obtained by sending ques-
tionnaires to experts—i.e., people with knowledge and 
expertise regarding malaria in the concerned countries. 
Experts who published on malaria diagnostic methods 
between 2005 and 2015 were identified through a Pub-
Med search using the search phrase “malaria” AND “diag-
nostic test” AND (“Congo” OR “Uganda” OR “Kenya”).
The questionnaire elicited the experts’ knowledge on 
the sensitivity and specificity of rapid diagnostic tests 
light microscopy, and reported history of fever in the 
previous 14  days, for diagnosing malaria in children 
under five in the concerned countries (see Additional 
file 2). To capture the uncertainty in the elicited opinions 
and to keep the burden as minimal as possible, experts 
were asked to provide a minimal and maximal possible 
value. For each test characteristic, the prior information 
provided by the different experts were combined into a 
single Beta distribution. First, 10,000 random samples 
were generated per expert, assuming a uniform distribu-
tion between the experts’ minimal and maximal value. 
These simulations were then combined into a single vec-
tor, implying that all experts were given an equal weight. 
Finally, a Beta distribution was fitted to this joint distri-
bution using maximum likelihood, via the fitdist function 
in the fitdistrplus package for R 3.4.3. [26]. Additional 
file 3 provides example R code for this process.
Results
Survey data from 13,573 children under 5 years old were 
used in the analysis, including: 6941 children from the 
Democratic Republic of the Congo, 4072 children from 
Uganda, 2560 children from Kenya. Table  1 presents 
apparent malaria prevalence by country and diagnos-
tic test. Across all tests, Kenya showed a lower apparent 
prevalence than the Democratic Republic of the Congo 
and Uganda. The apparent prevalence found by light 
microscopy was systematically lower than the ones based 
on rapid diagnostic tests.
Table  2 shows the obtained test results according to 
possible test combinations. The proportion of children 
who had a positive result with both tests was similar in 
the Democratic Republic of the Congo and Uganda, i.e., 
18% (95% CI 17–19%) and 16% (95% CI 15–17%), respec-
tively. In Kenya, only 3.7% (95% CI 3.0–4.5%) were posi-
tive on both tests. the proportion of children who had 
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negative results on both tests was 66% (95% CI 65–67%) 
in the Democratic Republic of the Congo, 68% (95% CI 
66–69%) in Uganda, and 91% (95% CI 90–92%) in Kenya.
Prior information on the sensitivity and specificity of 
the diagnostic methods was available from six experts on 
malaria in sub-Saharan countries (one from the Demo-
cratic Republic of the Congo, two from Uganda and three 
from Kenya; see Additional file  4). Table  3 shows the 
resulting Beta distributions for the sensitivity and speci-
ficity of rapid diagnostic test and light microscopy in 
each considered country.
Convergence was obtained for all three countries. 
Table  4 shows the estimated true malaria prevalence in 
the three considered countries, as well as the estimated 
diagnostic method characteristics. Similar true malaria 
prevalence was estimated for the Democratic Republic of 
the Congo (20%) and Uganda (22%), while the estimate for 
Kenya was considerably lower (1%). Across all countries, 
rapid diagnostic tests showed satisfactory sensitivities and 
specificities, while light microscopy had variable sensitivi-
ties, but satisfactory specificities. More detailed results, 
including convergence statistics for each parameter and 
Bayesian measures of complexity and fit, are available in 
Additional file 5. The one-way sensitivity analyses showed 
that all models were robust against the specification of 
each individual informative prior (see Additional file 6).
Table 1 Positive samples (x) and apparent prevalence (AP, %) with 95% exact confidence interval for malaria by country 
and diagnostic method
RDT rapid diagnostic test
Diagnostic test DRC (n = 6941) Uganda (n = 4072) Kenya (n = 2560)
x AP (95% CI) x AP (95% CI) x AP (95% CI)
RDT 2090 30 (29–31) 1210 30 (28–31) 209 8.2 (7.1–9.3)
Microscopy 1523 22 (21–23) 761 19 (18–20) 113 4.4 (3.7–5.3)
Table 2 Number of individuals as a function of the results 
of the two diagnostic methods for the Democratic Repub-
lic of the Congo (n = 6941), Uganda (n = 4072) and Kenya 
(n = 2560)
RDT rapid diagnostic test









1 1 1237 663 94
1 0 853 547 116
0 1 286 98 19
0 0 4565 2764 2332
Table 3 Prior information on sensitivity and specificity of different diagnostic methods for malaria in three sub-Saharan 
countries
RDT rapid diagnostic test, P025 2.5th percentile, P975 97.5th percentile
Diagnostic test Sensitivity Specificity
Fitted distribution Mean (P025–P975) Fitted distribution Mean (P025–P975)
Democratic Republic of the Congo
 RDT Beta (501, 44) 0.92 (0.90–0.94) Beta (466, 67) 0.88 (0.85–0.90)
 Microscopy Beta (33, 1.7) 0.95 (0.86–1.00) Beta (27, 3.3) 0.89 (0.76–0.97)
Uganda
 RDT Beta (25, 4.5) 0.85 (0.70–0.95) Beta (8.3, 2.5) 0.77 (0.49–0.96)
 Microscopy Beta (7.8, 5.7) 0.58 (0.32–0.82) Beta (32, 1.7) 0.95 (0.86–1.00)
Kenya
 RDT Beta (25, 6.2) 0.80 (0.65–0.92) Beta (17, 7.8) 0.68 (0.49–0.85)
 Microscopy Beta (27, 7.5) 0.78 (0.64–0.90) Beta (16, 3.5) 0.82 (0.62–0.95)
Table 4 Estimated (mean and 95% uncertainty interval) 
true malaria prevalence and diagnostic methods’ sensitiv-
ity and specificity by country
RDT rapid diagnostic test, DRC the Democratic Republic of the Congo
Parameter DRC Uganda Kenya
True prevalence 0.20 (0.17–0.23) 0.22 (0.09–0.32) 0.01 (0.00–0.03)
RDT, sensitivity 0.92 (0.90–0.94) 0.84 (0.69–0.94) 0.78 (0.63–0.90)
RDT, specificity 0.86 (0.83–0.88) 0.86 (0.76–0.95) 0.92 (0.91–0.94)
Microscopy, sensitiv‑
ity
0.90 (0.78–0.98) 0.61 (0.41–0.81) 0.77 (0.63–0.89)
Microscopy, speci‑
ficity
0.95 (0.92–0.97) 0.93 (0.85–0.98) 0.96 (0.95–0.98)
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Including reported history of fever in the previous 
14  days as a third diagnostic method in the model did 
not influence the main model estimates (see Additional 
file  1). The estimated true prevalence remained nearly 
identical—i.e., 21% (95% UI 17–24%) in the Democratic 
Republic of the Congo, 22% (95% UI 8.9–33%) in Uganda 
and 1% (95% UI 0–3%) in Kenya. Across countries, the 
estimated sensitivity of reported history of fever in the 
previous 14 days as diagnostic method for malaria ranged 
from 53 to 57%, while its specificity ranged from 61 to 
74%.
Discussion
A Bayesian framework was used to estimate the true 
malaria prevalence from malaria household surveys in 
three sub-Saharan African countries, using survey results 
of two conditionally dependent diagnostic methods, 
and prior information on the conditionally independ-
ent sensitivities and specificities of evaluated tests [21]. 
The adopted modelling approach produced optimized 
prevalence estimations that allow comparability across 
different settings. Indeed, despite unprecedented levels 
of intervention coverage across sub-Saharan Africa since 
early 2000s [1], true malaria prevalence in children under 
five in two of the three selected countries (i.e., the Demo-
cratic Republic of the Congo and Uganda) was still esti-
mated to be around 20%. In Kenya, on the other hand, 
the true malaria prevalence was estimated at 1% (even 
though the apparent prevalence varied from 4 to 40% 
according to the test, only 2% of children had a positive 
result for both tests).
Differences in the accuracy between diagnostic meth-
ods can result in a considerable variation in malaria 
prevalence estimations, when test sensitivity and speci-
ficity are not taken into account [19]. As found in the 
current study, the apparent malaria prevalence in each 
country varied widely according to the test used. In 
Uganda, for instance, the screening with rapid diagnos-
tic tests yielded a malaria prevalence of 30%, while the 
microscopic detection of parasites in blood smears gen-
erated a much lower malaria prevalence of 19%. A simi-
lar observation was made in Kenya, where the malaria 
prevalence obtained with rapid diagnostic test was twice 
as high as that obtained with microscopic detection, 
i.e., 8% versus 4%. These differences are linked to a dif-
ferential bias across diagnostic methods (e.g., more sub-
microscopic cases in settings with lower transmission or 
higher levels of prior treatment [5]), resulting in differ-
ent but unknown rates of false positive and false negative 
results. Indeed, in absence of a gold standard test [27], 
neither the sensitivity nor the specificity of the tests used 
in household surveys is known with certainty, introduc-
ing additional uncertainty (through Beta distributions 
of sensitivity and specificity values reported by malaria 
experts) when modelling apparent prevalence to estimate 
true prevalence.
Across countries, rapid diagnostic tests showed satisfac-
tory sensitivities and specificities, while light microscopy 
had variable sensitivities, but satisfactory specificities. 
Indeed the estimated sensitivity of microscopy varied from 
61% in Uganda over 77% in Kenya to 90% in the Democratic 
Republic of the Congo. In addition to differences in the 
observed numbers of positive and negative cases, this vari-
ability may also be a result of differences in expert opinion. 
Indeed, experts evaluated the microscopy results as show-
ing more false negatives in Uganda compared to Kenya and 
the Democratic Republic of the Congo, with mean sensi-
tivities of 58, 78 and 95%, respectively, which could be an 
indication of their differential evaluation of the environ-
ment (e.g., better microscopists, better storage conditions). 
In this respect, it can be noted that the values provided by 
the experts from Uganda were in line with some popula-
tion-based survey studies that calculated the sensitivity of 
the microscopy using the PCR as gold standard (e.g., [5]). 
On the other hand, the values provided by the experts from 
Kenya and the Democratic Republic of the Congo seemed 
to be higher than those reported in population-based sur-
vey studies where PCR was used as gold standard (e.g., [28, 
29]). Nonetheless, the one-way sensitivity analyses showed 
that the true prevalence estimates in all three countries 
were robust against misspecification of this prior.
Besides considering that none of diagnostic methods 
used in household surveys is the gold standard for malaria 
(imperfect tests) and that those diagnostic methods are 
not completely independent of each other, the adopted 
Bayesian modelling approach was able to impose consist-
ency between the estimates for true prevalence and for 
the test characteristics. This allowed resolving possible 
discrepancies between the prior information (i.e., expert 
opinion about sensitivity and specificity) and the observed 
data, which are not unusual in Bayesian models [16]. For 
example, the low number of individuals with positive tests 
in Kenya was inconsistent with the moderate specificities 
elicited for rapid diagnostic test (68%) and light micros-
copy (82%), however specificities estimated using the 
Bayesian model were high (92 and 96%, respectively). On 
the other hand, it should be noted that Bayesian models 
with different dependency structures can provide dif-
ferent parameter estimates, in spite of their similarity 
in terms of adjustment measures. However, when only 
few tests are available, as in the current study, it may be 
nearly impossible to distinguish between different classes 
of models for the dependence structure, and unverifiable 
modelling assumptions are needed to make inference [30].
Extending the Branscum et  al. [21] model to allow 
for simultaneous consideration of three conditionally 
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dependent diagnostics methods, allowed evaluating the 
added value of reported fever history within the past 
14 days as a malaria diagnostic. Although fever is used in 
the field as a proxy indicator of malaria illness, the added 
value of the DHS/MIS fever indicator in studying malaria 
epidemiology could not be shown. This is not unsurpris-
ing, as reported history of fever in the previous 14 days is 
too unspecific for current malaria status [31].
Accurate and timely information on numbers and 
trends in malaria-related cases and deaths is a key require-
ment for tracking the progress of malaria control and 
elimination efforts [32]. In countries with poor surveil-
lance systems, such as in sub-Saharan Africa countries, 
this information can only be obtained by modelling the 
relationship between parasite prevalence and case inci-
dence, or mortality [3, 33, 34]. The estimates intend to fill 
gaps in reported data [35]; but because they rely on rela-
tionships between variables that are uncertain, and draw 
on data that may be imprecisely measured, the estimates 
usually have a considerable degree of uncertainty [36]. 
Researchers from the Malaria Atlas Project (MAP) have 
developed a Bayesian hierarchical model intended to han-
dle the different sources of uncertainty (e.g., uncertainty 
in the sample size and spatio-temporal density of preva-
lence surveys, uncertainty in the relationship between 
malaria prevalence and environmental covariates) with 
the aim of predicting a spatio-temporal cube of Plasmo-
dium falciparum prevalence at 5 × 5 km resolution across 
all endemic African countries [3, 33]. However, most 
malaria risk maps produced by this global initiative [3, 33] 
and by other research groups [37] did not consider that 
malaria prevalence from national and sub-national house-
hold surveys can be influenced by the uncertainty in the 
accuracy of diagnostic methods used during the surveys. 
Repeating the here adopted approach across multiple 
countries and with more experts may, therefore, provide a 
potential contribution to the current MAP results.
The main limitations of the current study may be 
related to the assumption of a single sensitivity and 
specificity for each diagnostic method within each coun-
try, irrespective of the endemicity and dynamics of the 
malaria transmission at sub-national and local levels. A 
negative correlation between the intensity of malaria 
transmission and the proportion of infections with low 
parasite densities has been repeatedly described [38, 39], 
thus influencing the limit of detection of light micros-
copy and rapid diagnostic tests and consequently the 
sensitivity of those tests. The geographical variation in 
the presence of histidine-rich protein 2 (Pfhrp2) in P. 
falciparum parasites across the country can also influ-
ence the accuracy of rapid diagnostic tests for detecting 
malaria [40]. This spatial heterogeneity in the perfor-
mance of diagnostic methods can be taken into account 
in the approach presented here, but it will require more 
detailed information from malaria experts about the rela-
tionships between the performance of diagnostic meth-
ods and relevant covariates, as well as information on the 
distribution of these covariates [20].
Conclusion
In absence of a true gold standard test, Bayesian model-
ling remains a powerful tool for estimating true malaria 
burden. The combination of results from two malaria 
diagnostic methods used in household surveys with 
expert opinion about the performance of the diagnos-
tic methods offers the possibility to compare prevalence 
estimates between countries and over time in a same 
country. This comparability is key when monitoring and 
evaluating malaria control and elimination efforts.
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